CoChat

Equivalence of complex drug products: advances in and challenges for current regulatory frameworks

Open access
Hussaarts, Leonie, Mühlebach, Stefan, Shah, Vinod P., McNeil, Scott, Borchard, Gerrit, Flühmann, Beat, Weinstein, Vera, Neervannan, Sesha, Griffiths, Elwyn, Jiang, Wenlei, Wolff‐Holz, Elena, Crommelin, Daan J.A., de Vlieger, Jon S.B. · 2017 · Annals of the New York Academy of Sciences
Cited by 88

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Biotechnology and nanotechnology provide a growing number of innovator‐driven complex drug products and their copy versions. Biologics exemplify one category of complex drugs, but there are also nonbiological complex drug products, including many nanomedicines, such as iron–carbohydrate complexes, drug‐carrying liposomes or emulsions, and glatiramoids. In this white paper, which stems from a 1‐day conference at the New York Academy of Sciences, we discuss regulatory frameworks in use worldwide (e.g., the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization) to approve these complex drug products and their follow‐on versions. One of the key questions remains how to assess equivalence of these complex products. We identify a number of points for which consensus was found among the stakeholders who were present: scientists from innovator and generic/follow‐on companies, academia, and regulatory bodies from different parts of the world. A number of topics requiring follow‐up were identified: (1) assessment of critical attributes to establish equivalence for follow‐on versions, (2) the need to publish scientific findings in the public domain to further progress in the field, (3) the necessity to develop worldwide consensus regarding nomenclature and labeling of these complex products, and (4) regulatory actions when substandard complex drug products are identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/nyas.13347

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 88

Metadata

Authors
Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S., Borchard, G., Flühmann, B., Weinstein, V., Neervannan, S., Griffiths, E., Jiang, W., Wolff‐Holz, E., Crommelin, D. J. A., & de Vlieger, J. S. B.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2017-04-26
Volume
1407
Issue
1
Pages
39-49
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2609525945
Cited by
88
References
2
FWCI
3.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. https://app.cochat.ai/papers/10.1111/nyas.13347
The paper
Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S., Borchard, G., Flühmann, B., Weinstein, V., Neervannan, S., Griffiths, E., Jiang, W., Wolff‐Holz, E., Crommelin, D. J. A., & de Vlieger, J. S. B. (2017). Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.13347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.